1Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, Turkey
2Department of Family Medicine, Faculty of Medicine, Firat University, Elazig, Turkey
3Department of Biochemistry, Faculty of Medicine, Firat University, Elazig, Turkey
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aim: The most important goal in the treatment of Diabetes Mellitus is to protect patients from micro and macro complications. Inflammatory cytokines and betatrophin have been reported to play a role in diabetic micro and macro complications. This study aimed to investigate the effect of serum Betatrophin, TNF-α and IL-6 levels on diabetic micro and macro complications in patients with type 2 Diabetes Mellitus.
Materials and Methods: This case-control study was conducted with 91 type 2 Diabetes Mellitus (T2DM) patients between January-December 2018. Case series with 91 patients divided into three groups were included; 31 T2DM patients without diabetic complications (group 1=control), 30 patients with diabetic microvascular complications (group 2) and 30 patients with diabetic macrovasculer complications (group 3). Blood was collected to evaluate biochemical parameters, TNF-α, IL-6 and betatrophin.
Results: Betatrophin level was high in patients with renitopathy (p=0.042) and diabetic foot (p=0.036). TNF-α levels were higher in patients with both microvascular and macrovascular complications compared to the control group (p0.001). IL-6 levels were increased only in the group with macrovascular complications (p=0.027).
Conclusion: Betatrophin, TNF-α and IL-6 were associated with diabetic complications. Larger studies are warranted to establish the real impact of this finding.
Keywords: Betatrophin; diabetes mellitus; IL-6; TNF-α; Type 2/complicationsDownload PDF